The use of colposcopic punch biopsy in the management of abnormal cervical cytology: a 5-year retrospective audit.


Journal

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
ISSN: 1364-6893
Titre abrégé: J Obstet Gynaecol
Pays: England
ID NLM: 8309140

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 20 9 2018
medline: 9 5 2019
entrez: 20 9 2018
Statut: ppublish

Résumé

The aim of this study was to determine the accuracy of colposcopic punch biopsy to detect cervical epithelial neoplasia (CIN) II + in patients with abnormal cervical cytology and the major colposcopic findings in patients who underwent a loop electrosurgical excision procedure (LEEP), subsequently. A total of 231 patients with abnormal cervical cytology who underwent a colposcopy guided cervical biopsy and subsequent LEEP were analysed. The mean age was 33.4 ± 8.7 years. CIN II + rate on LEEP pathology was significantly higher in patients with high-grade cytology, compared to those with a low-grade cytology (92 vs. 55%, p < .0001). CIN II + was found in 80, 98 and 100% of colpocopic biopsies of patients with LSIL, HSIL and AGC, respectively. The overall concordance rate between a colposcopic biopsy and LEEP was 41% with a kappa coefficient. The overall underestimation of CIN II + was 10.5%. On a patient-based analysis, the sensitivity, specificity, PPV and NPV of colposcopic biopsy were 89.4, 47.1, 79.5 and 66%, respectively. More than two cervical biopsies had 100% sensitivity for CIN II + on LEEP pathology. The specificity and PPV decreased with increasing number of cervical biopsies. A see-and-treat strategy may be considered for high-grade cytologies. Patients with a low-grade cytology should be managed with more than two colposcopic biopsies.

Identifiants

pubmed: 30230394
doi: 10.1080/01443615.2018.1468740
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110-114

Auteurs

Ilker Kahramanoglu (I)

a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.

Fuat Demirkiran (F)

a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.

Hasan Turan (H)

a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.

Tugan Bese (T)

a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.

Nevin Yilmaz (N)

a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.

Sennur Ilvan (S)

b Department of Pathology, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.

Macit Arvas (M)

a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine , Istanbul University , Istanbul , Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH